View in EDS HTML Full Text PDF Full Text

CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.

Saved in:
Bibliographic Details
Title: CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.
Authors: Ganzel C; Hematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel., Frisch A; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel., Wolach O; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center - Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Moshe Y; Department of Hematology and Bone Marrow Transplantation Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel., Krayem B; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel., Dor N; Hematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel., Broide E; Flow Cytometry Laboratory, Shaare Zedek Medical Center, Jerusalem, Israel., Benayoun E; Flow Cytometry Laboratory, Shaare Zedek Medical Center, Jerusalem, Israel., Rowe JM; Hematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel.; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel., Ofran Y; Hematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel.
Source: British journal of haematology [Br J Haematol] 2025 Feb; Vol. 206 (2), pp. 551-555. Date of Electronic Publication: 2024 Dec 25.
Publication Type: Journal Article; Clinical Trial
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39721590
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ganzel+C%22">Ganzel C</searchLink>; Hematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel.<br /><searchLink fieldCode="AU" term="%22Frisch+A%22">Frisch A</searchLink>; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.<br /><searchLink fieldCode="AU" term="%22Wolach+O%22">Wolach O</searchLink>; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center - Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Moshe+Y%22">Moshe Y</searchLink>; Department of Hematology and Bone Marrow Transplantation Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Krayem+B%22">Krayem B</searchLink>; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.<br /><searchLink fieldCode="AU" term="%22Dor+N%22">Dor N</searchLink>; Hematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel.<br /><searchLink fieldCode="AU" term="%22Broide+E%22">Broide E</searchLink>; Flow Cytometry Laboratory, Shaare Zedek Medical Center, Jerusalem, Israel.<br /><searchLink fieldCode="AU" term="%22Benayoun+E%22">Benayoun E</searchLink>; Flow Cytometry Laboratory, Shaare Zedek Medical Center, Jerusalem, Israel.<br /><searchLink fieldCode="AU" term="%22Rowe+JM%22">Rowe JM</searchLink>; Hematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel.; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.<br /><searchLink fieldCode="AU" term="%22Ofran+Y%22">Ofran Y</searchLink>; Hematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220372544%22">British journal of haematology</searchLink> [Br J Haematol] 2025 Feb; Vol. 206 (2), pp. 551-555. <i>Date of Electronic Publication: </i>2024 Dec 25.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0372544 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1365-2141 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200071048%22">00071048 </searchLink><i>NLM ISO Abbreviation: </i>Br J Haematol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39721590
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/bjh.19967
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 551
    Titles:
      – TitleFull: CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ganzel C
      – PersonEntity:
          Name:
            NameFull: Frisch A
      – PersonEntity:
          Name:
            NameFull: Wolach O
      – PersonEntity:
          Name:
            NameFull: Moshe Y
      – PersonEntity:
          Name:
            NameFull: Krayem B
      – PersonEntity:
          Name:
            NameFull: Dor N
      – PersonEntity:
          Name:
            NameFull: Broide E
      – PersonEntity:
          Name:
            NameFull: Benayoun E
      – PersonEntity:
          Name:
            NameFull: Rowe JM
      – PersonEntity:
          Name:
            NameFull: Ofran Y
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2025 Feb
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1365-2141
          Numbering:
            – Type: volume
              Value: 206
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: British journal of haematology
              Type: main
ResultId 1